An Optional Two Year Follow Up Study to Study CP005A
|ClinicalTrials.gov Identifier: NCT01604018|
Recruitment Status : Completed
First Posted : May 23, 2012
Last Update Posted : May 24, 2012
Cat allergy is an increasingly prevalent condition affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma.
The purpose of this optional observational follow-on study is to further evaluate rhinoconjunctivitis symptoms on exposure to cat dander in the EEC among subjects who completed all dosing visits in study CP005 and all visits in study CP005A approximately two years after the start of treatment.
|Condition or disease|
|Cat Allergy Rhinoconjunctivitis|
|Study Type :||Observational|
|Actual Enrollment :||51 participants|
|Official Title:||An Optional Two Year Follow Up Study to Evaluate the Continued Efficacy of Cat-PAD ToleroMune Peptide Immunotherapy in Cat Allergic Subjects Following Challenge to Cat Allergen in an Environmental Exposure Chamber|
|Study Start Date :||February 2012|
|Actual Primary Completion Date :||April 2012|
|Actual Study Completion Date :||April 2012|
Subjects previously randomized to receive placebo in study CP005 and completed CP005A.
Cat-PAD Group 1
Subjects previously randomized to receive Cat-PAD dose 1 in study CP005 and completed CP005A.
Cat-Pad Group 2
Subjects previously randomized to receive Cat-PAD dose 2 in study CP005 and completed CP005A.
- Total Rhinoconjunctivitis Symptom Score [ Time Frame: 102-106 weeks after the start of treatment in CP005 ]
- Total Symptom scores for ocular and nasal symptoms [ Time Frame: 102-106 weeks after the start of treatment in CP005 ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01604018
|Mississauga, Ontario, Canada|
|Principal Investigator:||Peter Couroux, MD||Cetero Research, San Antonio|